CompuCyte and Genetics Institute to develop theranostics:
This article was originally published in Clinica
Executive Summary
CompuCyte and Genetics Institute (GI) are to collaborate on developing diagnostic tests that help select patients for drug therapy and follow them during treatment - so-called theranostics. Under the agreement, CompuCyte will develop cell-based assays for monitoring the effects of drugs known as cell adhesion inhibitors. GI, a unit of American Home Products' pharmaceutical division Wyeth-Ayerst Laboratories, is developing cell adhesion inhibitors to treat vascular and inflammatory diseases. The assays will be performed with Compuctye's OneCyte laser scanning technology.